| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Varenicline-d4 Basic information |
| Product Name: | Varenicline-d4 | | Synonyms: | Varenicline-d4;7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline-7,7,9,9-d4;Varenicline Nitroso D4;D4-Varenicline | | CAS: | 2183239-01-0 | | MF: | C13H13N3 | | MW: | 211.27 | | EINECS: | | | Product Categories: | | | Mol File: | 2183239-01-0.mol |  |
| | Varenicline-d4 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Water: 0.0877 mg/mL | | form | A solid | | Water Solubility | Water: 0.0877 mg/mL |
| | Varenicline-d4 Usage And Synthesis |
| Description | Varenicline-d4 is intended for use as an internal standard for the quantification of varenicline by GC- or LC-MS. Varenicline is a full agonist of α7 subunit-containing neuronal nicotinic acetylcholine receptors (nAChRs; EC50 = 18 μM) and a partial agonist of α4β2 subunit-containing nAChRs (EC50 = 2.3 μM). Formulations containing varenicline have been used as aids in smoking cessation. | | Uses | Varenicline-d4 is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Mihalak KB, et al. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.Mol Pharmacol.2006 Sep;70(3):801-5. Epub 2006 Jun 9. DOI:10.1124/mol.106.025130
[3] Bagdas D, et al. New insights on the effects ofvareniclineon nicotine reward, withdrawal and hyperalgesia in mice.Neuropharmacology.2018 Aug;138:72-79. DOI:10.1016/j.neuropharm.2018.05.025 |
| | Varenicline-d4 Preparation Products And Raw materials |
|